This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Scully, C. Articles by Bagan, J.-V. Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?

ADVERSE DRUG REACTIONS IN THE OROFACIAL REGION

Eastman Dental Institute for Oral Health Care Sciences, University College, University of London, 256 Gray’s Inn Road, London WC1X 8LD, UK;

J.-V. Bagan

Valencia University and Hospital, General Universitario de Valencia, Avenida 3 Cruces, 46014 Valencia, Spain

Correspondence: ^* corresponding author, scully.c{at}eastman.ucl.ac.uk

Abstract

Introduction

Drug-related Disorders of the Salivary Glands

(1) DRUG-RELATED XEROSTOMIA

(a) Antidepressants

(b) Antipsychotics

(c) Antihistamines

(d) Muscarinic receptor antagonists used to treat overactive bladder

(e) Alpha receptor antagonists used to treat overactive bladder

(f) Diuretics

(g) Antihypertensives

(h) Appetite suppressants

(i) Decongestants and ''cold cures''

(j) Bronchodilators

(k) Skeletal muscle relaxants

(l) Antimigraine drugs

(m) Opioids, benzodiazepines, hypnotics, and drugs of abuse

(n) H2 receptor antagonists and proton-pump inhibitors

(o) Cytotoxic drugs

(p) Retinoids

(q) Anti-HIV drugs

(r) Cytokines

(2) DRUG-RELATED SALIVARY GLAND SWELLING

(3) DRUG-RELATED SALIVARY GLAND PAIN

(4) DRUG-RELATED HYPERSALIVATION

(5) DISCOLORATION OF SALIVA

Drug-related Disorders of Taste

Drug-related Mucosal Disorders

(1) ORAL ULCERATION

(a) Drug-related oral burns

(b) Drug-related aphthous-like ulceration

(c) Fixed drug eruptions

(d) Drug-related mucositis

(e) Drug-related neoplasms and potentially malignant lesions

(f) Drug-related pemphigoid-like reactions and other bullous disorders

(g) Drug-related pemphigus

(h) Drug-related erythema multiforme

(i) Drug-related toxic epidermal necrolysis

(j) Drug-related lupus-like disorders

(2) DRUG-RELATED WHITE LESIONS

(a) Burns (see above) (b) Lichenoid eruptions

(c) Lupoid reactions (see above) (d) Candidosis

(e) Papillomas

(f) Hairy leukoplakia

(g) Leukoplakia

Drug-related Mucosal Pigmentation

(1) DRUG-RELATED SUPERFICIAL TRANSIENT DISCOLORATION

(2) DRUG-RELATED INTRINSIC PIGMENTATION

Drug-related Swellings

(1) DRUG-RELATED GINGIVAL ENLARGEMENT

(2) DRUG-RELATED LIP AND MUCOSAL SWELLING

Drug-related Cheilitis

Drug-related Neuropathies

(1) DRUG-RELATED TRIGEMINAL NEUROPATHIES

(2) DRUG-RELATED INVOLUNTARY FACIAL MOVEMENTS

(3) DRUG-RELATED OROFACIAL PAIN AND ORAL DYSESTHESIA

Drug-related Oral Malodor (Halitosis)

Drug-related Tooth Discoloration

Summary

REFERENCES

	Abstract

TOP Next

Key Words: Oral • drugs • adverse reactions • salivary • mucosa • ulcers • taste

	Introduction

TOP Previous Next

 
A wide spectrum of drugs can sometimes give rise to numerous adverse oral manifestations, particularly dry mouth, taste disturbances, oral mucosal ulceration, and/or swelling. A review of the 200 most frequently prescribed drugs (in the USA in 1992) showed the most frequent oral adverse drug reactions (ADRs) to be dry mouth (80.5%), dysgeusia (47.5%), and stomatitis (33.9%) (Smith and Burtner, 1994). However, few randomized double-blind controlled studies have been conducted, and therefore most of the evidence available at the present time is of low level, originating only from case reports, small series, or non-peer-reviewed reports of adverse drug reactions.

This paper reviews the literature based on a MEDLINE search to April, 2003, and highlights the more common and significant adverse oral consequences of drug therapy. When relevant, it provides sources of other suitable reports: It does not include details on the oral side-effects of foodstuffs, tobacco, alcohol, or recreational drugs, or the adverse effects of drugs upon the dentition.

	Drug-related Disorders of the Salivary Glands

TOP Previous Next

 
(1) DRUG-RELATED XEROSTOMIA
Dry mouth has a variety of possible causes (Scully, 2003) (Table 1). Common habits such as tobacco smoking, alcohol use (including in mouthwashes), and the consumption of beverages containing caffeine (coffee, some soft drinks) can cause some oral dryness. Drugs are the most common cause of reduced salivation (Table 1, Fig. 1) (Scully, 2003). The drugs most commonly implicated include: alpha receptor antagonists for treatment of urinary retention; amphetamines; anticholinergics; antidepressants (serotonin agonists, or noradrenaline and/or serotonin re-uptake blockers); antihistamines; antihypertensive agents; antimigraine agents; antipsychotics such as phenothiazines; appetite suppressants; atropinics; benzodiazepines, hypnotics, opioids, and drugs of abuse; bronchodilators; cytokines; cytotoxics; decongestants and ‘cold cures’; diuretics; histamine H2 antagonists and proton pump inhibitors; muscarinic receptor antagonists for the treatment of overactive bladder; opiates; protease inhibitors; radioiodine; retinoids; and skeletal muscle relaxants (Scully, 2003).

View larger version (87K): [in this window] [in a new window]   Figure 1. Drug-induced xerostomia.

Dry mouth is a common complaint in patients treated for hypertensive, psychiatric, or urinary problems (Streckfus, 1995) and in the elderly (Vissink et al., 1992; Loesche et al., 1995), mainly as a consequence of the large number of drugs used (Fox, 1998; Närhi et al., 1999) and polypharmacy (Loesche et al., 1995; Nederfors, 1996; Fox, 1998). For example, 63% of hospitalized patients and 57% of outpatients complained of dry mouth, and in all patients, the use of psychiatric drugs was the main cause (Pajukoski et al., 2001).

Age and medication seem to play a more important role in individuals with objective evidence of hyposalivation, while female gender and psychological factors are important in individuals with subjective oral dryness (Bergdahl and Bergdahl, 2000).

Hypnotics are also commonly used by the elderly, and most users report ADRs, mainly dry mouth (30%) (Wishart et al., 1981; Busto et al., 2001). In the elderly using non-prescription products—most frequently, dimenhydrinate (21%), acetaminophen (paracetamol) (19%), diphenhydramine (15%), alcohol (13%), and herbal products (11%)—mild ADRs were reported by 75%, the most common complaint being dry mouth (Sproule et al., 1999).

In a large survey of 3311 evaluatable questionnaires, 21.3% of men and 27.3% of women reported dry mouth, with women statistically reporting higher prevalence of dry mouth than men (Nederfors, 1996). Dry mouth was significantly age-related, and there was a strong co-morbidity between reported prevalence of dry mouth and ongoing pharmacotherapy. Unstimulated salivary flow rates were lower among older persons who were female or taking antidepressants, and higher among smokers or people who were taking hypolipidemic drugs (Thomson et al., 2000). It is clear that medication is a better predictor of risk status for dry mouth than either age or gender (Field et al., 2001).

Even in elderly patients with advanced cancer, dry mouth was the fourth most common symptom (78% of patients), but the usual cause was drug treatment, and there was an association with the number of drugs prescribed (Davies et al., 2001). That is not to say that disease can always be excluded as a cause of dry mouth; for example, saliva secretion is more affected by xerogenic drugs and autonomic nervous dysfunction in patients with non-insulin-dependent diabetes than in non-diabetic controls (Meurman et al., 1998).

Furthermore, the cause for which the drug is being taken may also be important. For example, patients with anxiety or depressive conditions may complain of dry mouth even in the absence of drug therapy or evidence of reduced salivary flow. It is thus important to recognize that some patients complaining of a drug-related dry mouth have no evidence of a reduced salivary flow or a salivary disorder, and there may then be a psychogenic reason for the complaint.

Several different mechanisms account for drug-related dry mouth, but an anticholinergic action underlies many: The M3-muscarinic receptors (M3R) mediate parasympathetic cholinergic neurotransmission to salivary (and lacrimal) glands, but other receptors may also be involved (Kawaguchi and Yamagishi, 1995).

(a) Antidepressants
Early antidepressant medications such as tricyclic antidepressants (TCAs) unfortunately also blocked histaminic, cholinergic, and alpha1-adrenergic receptor sites, causing ADRs such as dry mouth. Men and women may differ in their pharmacokinetic responses to TCAs, in several autonomic indices, and in various adrenergic receptor-mediated responses. Emerging evidence also suggests that women, relative to men, may have a lower rate of brain serotonin synthesis and a greater sensitivity to the depressant effects of tryptophan depletion (Pomara et al., 2001). Finally, the ultrarapid metabolizer phenotype of the enzyme cytochrome P4502D6 (Laine et al., 2001) may be a cause of non-responsiveness to antidepressant drug therapy, and the subsequent prescribing of high doses of antidepressants to such patients leads to an increased risk for ADRs; however, normalization of the metabolic status of ultrarapid metabolizers by the inhibition of cytochrome activity, such as with paroxetine, could offer a solution (Laine et al., 2001).

Newer antidepressants are essentially serotonin (5-hydroxytryptamine: 5HT) agonists, or block re-uptake of noradrenaline (norepinephrine) and/or serotonin. Members of the newer generation of antidepressants—including the selective serotonin re-uptake inhibitors (SSRIs) and multiple-receptor antidepressants (such as venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone)—target one or more specific brain receptor sites without, in most cases, activating unwanted sites such as histamine and acetylcholine (Feighner, 1999; Feighner and Overo, 1999). The SSRI produce no significant changes in salivation (Hunter and Wilson, 1995), but dry mouth may still be seen (e.g., fluoxetine) (Ellingrod and Perry, 1994; Shrivastava et al., 1994; Hunter and Wilson, 1995; Davis and Faulds, 1996; Boyd et al., 1997; Ravindran et al., 1997; Trindade et al., 1998). However, some SSRIs, such as paroxetine, appear to result in less dry mouth than seen with TCAs (Ravindran et al., 1997). Citalopram, the most selective SSRI, is well-tolerated (Feighner and Overo, 1999). Venlafaxine, a mixed-re-uptake inhibitor, may produce dry mouth (Gelenberg et al., 2000). The incidence of ADRs in recipients of venlafaxine XR is similar to that in patients receiving treatment with well-established SSRIs (Wellington and Perry, 2001). Duloxetine hydrochloride, a dual-re-uptake inhibitor of serotonin and norepinephrine, also can produce dry mouth (Detke et al., 2002), as can mianserin, a mainly post-synaptic serotonin 2A agonist (Dolberg et al., 2002). Nefazodone, which has moderate serotonin selective re-uptake blocking properties and direct 5-HT2 antagonism, can produce dry mouth in 19% vs. 13% in placebo (Lader, 1996). Reboxetine, a selective norepinephrine re-uptake inhibitor (selective NRI), causes less dry mouth than TCAs, though it produces dry mouth more frequently than placebo (36% vs. 16%) (Schatzberg, 2000; Versiani et al., 2002). Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), can also induce dry mouth (Anttila and Leinonen, 2001).

Bupropion hydrochloride, originally developed as an antidepressant, is a selective re-uptake inhibitor of dopamine and norepinephrine which was found to reduce nicotine withdrawal symptoms and the urge to smoke, but commonly produces dry mouth (Zwar and Richmond, 2002). Dry mouth is positively associated with mean bupropion metabolite concentrations, and is inversely related to patient weight (Johnston et al., 2001).

(b) Antipsychotics
Long-term drug treatment of schizophrenia with conventional phenothiazine antipsychotics such as fluphenazine is commonly associated with dry mouth (Adams and Eisenbruch, 2000).

However, newly developed antipsychotic drugs with more potent and selective antagonistic activity against the dopamine D(2) receptor may not necessarily be associated with a lower incidence of dry mouth. Olanzapine is an atypical antipsychotic which appears to produce dry mouth (Duggan et al., 2000). Significant correlations have been found in in vitro affinities of antipsychotics toward dopamine or other neuronal receptor systems and ADRs: for example, between the K(i) values for dopamine D(1) receptor, alpha (1)-adrenoceptor and histamine H(1) receptor), and the incidence of dry mouth (Sekine et al., 1999). Other atypical antipsychotics—including tiapride (Roger et al., 1998), lithium (Christodoulou et al., 1977; Chacko et al., 1987; Friedlander and Birch, 1990; Tohen et al., 2002), pipamperone dihydrochloride (Potgieter et al., 2002), quetiapine and risperidone (Srisurapanont et al., 2000; Mullen et al., 2001)—may produce dry mouth.

(c) Antihistamines
The therapeutic effects of most of the older antihistamines were associated with sedating effects on the central nervous system (CNS) and antimuscarinic effects including dry mouth (Gwaltney et al., 1996). Non-sedating antihistamines—most of which are histamine H1 receptor antagonists, such as acrivastine, astemizole, cetirizine, ebastine, fexofenadine, loratadine, mizolastine, and terfenadine, however—are not entirely free from ADRs, though there may be less dry mouth (Mattila and Paakkari, 1999).

(d) Muscarinic receptor antagonists used to treat overactive bladder
Overactive bladder (OAB)—a chronic, distressing condition characterized by symptoms of urgency (sudden overwhelming urge to urinate) and frequency (urinating more than eight times daily), with or without urge urinary incontinence (sudden involuntary loss of urine)—is treated with muscarinic receptor antagonists, which can lead to troublesome dry mouth.

Dry mouth is a common side-effect seen with immediate-release oxybutynin (Hay-Smith et al., 2002), but a significantly lower proportion of patients taking controlled-release oxybutynin have moderate to severe dry mouth or any dry mouth compared with those taking immediate-release oxybutynin (Versi et al., 2000). Tolterodine, a competitive muscarinic receptor antagonist, produces dry mouth (Jacquetin and Wyndaele, 2001; Layton et al., 2001), though few patients (< 2%) experience severe dry mouth (Zinner et al., 2002), and there is a 23% lower incidence of dry mouth reported with once-daily extended-release tolterodine capsules than with twice-daily immediate-release tablets (Clemett and Jarvis, 2001). Propiverine hydrochloride, a safe and effective antimuscarinic drug as effective as oxybutynin, has a lower severity and incidence of dry mouth (Noguchi et al., 1998; Madersbacher et al., 1999).

(e) Alpha receptor antagonists used to treat overactive bladder
Tamsulosin, a selective alpha 1A-adrenoreceptor antagonist, produces significantly less dry mouth than terazosin, a less selective alpha antagonist (Lee and Lee, 1997).

(f) Diuretics
Diuretic agents and psychotropics were the most commonly used xerostomic medications in one study of elderly patients, and were almost equally potent in reducing mean salivary flow rate (Persson et al., 1991). Thiazides may cause dry mouth (McCarron, 1984), but there appear to be few reports showing a relationship between diuretic use and dry mouth. Subjectively, xerostomia was experienced 10 times more frequently after ingestion of furosemide than placebo (Atkinson et al., 1989).

(g) Antihypertensives
The ganglion blockers and particularly the beta-blockers (beta-adrenoceptor antagonists) may cause dry mouth (Nederfors, 1996) thought to be associated with activation of CNS and salivary gland alpha 2-adrenergic receptors. Such antihypertensive drugs, or sympatholytics (reserpine, methyldopa, and clonidine), are now little used because of such prominent ADRs as dry mouth.

Newer centrally acting antihypertensives, with selective agonist effects on the imidazoline I1 brainstem-receptors in the rostral ventromedulla (RVLM), appear to modulate sympathetic activity and blood pressure without affecting salivary flow: Moxonidine and rilmenidine are examples of this new class.

Moxonidine can produce dry mouth, more frequently than placebo (Dickstein et al., 2000) but only in a minority (< 10%), and significantly less than with the older antihypertensives (Schachter, 1999). Rilmenidine produces little dry mouth (Reid, 2001).

ACE inhibitors, which block the ACE enzyme in the renin-angiotensin-aldosterone system, produce dry mouth in about 13% of patients (Mangrella et al., 1998).

(h) Appetite suppressants
Several appetite suppressants can cause dry mouth, including sibutramine (Richter, 1999; Bray, 2001), fenfluramine plus phentermine (Weintraub et al., 1992), and the herbal Ma Huang and Kola nut supplement (containing ephedrine alkaloids/caffeine) produce dry mouth (Boozer et al., 2002).

(i) Decongestants and "cold cures"
Decongestants such as pseudoephedrine (Wellington and Jarvis, 2001) and loratadine plus pseudoephedrine sulphate can result in dry mouth (Kaiser et al., 1998).

(j) Bronchodilators
Anti-asthma drugs can be associated with dry mouth (Thomson et al., 2002). The most common reported ADR after use of the bronchodilator tiotropium is dry mouth (Casaburi et al., 2000).

(k) Skeletal muscle relaxants
Tizanidine, an alpha 2-adrenoceptor agonist used for the relief of spasticity, can be associated with significant dry mouth (Taricco et al., 2000).

(l) Antimigraine drugs
Rizatriptan, a serotonin agonist used for the treatment of migraine, can induce dry mouth (Winner et al., 2002).

(m) Opioids, benzodiazepines, hypnotics, and drugs of abuse
Opioids are well-recognized causes of dry mouth (Bruera et al., 1999), and atropine, hyoscine, and atropinics have long been used to reduce secretions pre-operatively. Dry mouth is the only significant side-effect of transdermal scopolamine (hyoscine) (Gordon et al., 2001). Morphine (Bruera et al., 1999; Zacny, 2001), dihydrocodeine (Freye et al., 2001), and Tramadol (Scott and Perry, 2000) can produce dry mouth.

Benzodiazepines (such as diazepam) (Conti and Pinder, 1979; Elie and Lamontagne, 1984) and zopiclone, a cyclopyrrolone chemically unrelated to benzodiazepines (Wadworth and McTavish, 1993), can produce dry mouth.

Cannabis (Consroe et al., 1986; Grotenhermen, 1999) and Ecstasy (‘XTC’ or ‘E’: 3,4 methylenedioxy-methamphetamine; MDMA) (Peroutka et al., 1988; Milosevic et al., 1999) can produce dry mouth.

(n) H2 receptor antagonists and proton-pump inhibitors
H2-receptor antagonists produce dry mouth in 41% of recipients (Teare et al., 1995; Kaviani et al., 2001).

(o) Cytotoxic drugs
Dry mouth can be a consequence of exposure to agents used for chemotherapy of malignant neoplasms, such as retinol (Goodman et al., 1983), or 5-fluorouracil (McCarthy et al., 1998), but this is not invariable (Laine et al., 1992), and there is a paucity of data in this area.

(p) Retinoids
Systemic retinoids such as etretinate (Wishart et al., 1981), 13 cis-retinoic acid (Hennes et al., 1984), and isotretinoin (Oikarinen et al., 1995) can produce dry mouth.

(q) Anti-HIV drugs
Didanosine (Dodd et al., 1992; Valentine et al., 1992) and HIV protease inhibitors (Greenwood et al., 1998) can cause dry mouth.

(r) Cytokines
Alpha interferon therapy for the treatment of chronic hepatitis C infection (Cotler et al., 2000) can cause significant dry mouth. Interleukin-2 (rIL-2), when used, for example, for control of nasopharyngeal carcinoma, can also impair salivation (Chi et al., 2001), and major salivary gland dysfunction has been described in patients with hematological malignancies given interleukin-2-based immunotherapy after autologous stem cell transplantation (Nagler, 1998).

(2) DRUG-RELATED SALIVARY GLAND SWELLING
Some drugs have been related to salivary gland swelling (Table 2). Painless, usually bilateral, salivary gland enlargement (resembling sialosis) may be an occasional side-effect of phenylbutazone (Cohen and Banks, 1966; Murray-Bruce, 1966; Chimenes, 1971; Herman et al., 1974; Kaufman et al., 1977), oxyphenbutazone (Bosch et al., 1985), or chlorhexidine (Rushton, 1977). The bilateral sialadenitis observed in one adult following naproxen therapy (Knulst et al., 1995) was thought to be allergic in origin, since the affected patient also had a cutaneous rash. A similar mechanism has been proposed to underlie the salivary gland enlargement caused by intravenous radiological contrast media (Gattoni et al., 1991; Ilia et al., 1991). Clozapine, a novel antipsychotic agent, may cause transient salivary gland swelling (Vasile and Steingard, 1995) as well as sialorrhea (see below).

(4) DRUG-RELATED HYPERSALIVATION
Anticholinesterases are the main cause of hypersalivation (Table 3). Clozapine, an atypical antipsychotic drug claimed to have superior efficacy and to cause fewer motor adverse effects than typical antipsychotics for people with treatment-resistant schizophrenic patients, can cause hypersalivation (Wahlbeck et al., 2000). This may be ameliorated with atropine eye drops (Comley et al., 2000).

	Drug-related Disorders of Taste

TOP Previous Next

ACE inhibitors, anti-thyroids, beta-lactam antibiotics, biguanides, chlorhexidine, opiates, and protease inhibitors are particularly implicated. Up to 4% of patients treated with ACE inhibitors may have dysgeusia, although this adverse effect is self-limiting and reversible within a few months, even with continued therapy (Henkin, 1994). Newer therapies—such as the anti-HIV protease inhibitors (Scully and Diz, 2001), therapy with tripotassium dicitrato bismuthate chelate, clarithromycin, and lansoprazole therapy for H. pylori infection (Scott, 1998), terbinafine (Stricker et al., 1996), intravenous pentamidine (Glover et al., 1995), and isotretinoin (Halpern et al., 1996)—may cause some degree of loss of taste or altered taste.

There is preliminary evidence that alpha lipoic acid might improve dysgeusia, at least in idiopathic cases (Femiano et al., 2002), but the condition is best improved by reducing use of the offending drug.

	Drug-related Mucosal Disorders

TOP Previous Next

 
(1) ORAL ULCERATION
A wide range of etiologies, from burns to vesiculobullous disorders of various kinds, can result in oral ulceration. Many reports of mouth ulceration following drug use have been from non-specialists, and therefore their description as ‘aphthous’-like or other fairly specific entities can often be questioned, leading to some difficulty in accurately ascribing cause and effect.

(a) Drug-related oral burns
Oral desquamation or ulceration may follow burns from the accidental ingestion of caustics such as lime (Schier et al., 2002), from the local application of aspirin or toothache preparations, potassium tablets, pancreatic supplements, and other agents such as trichloracetic acid or hydrogen peroxide or from the use of various oral health care products (Kuttan et al., 2001). Sodium lauryl sulfate, present in some oral health care products, particularly dentifrices, may cause mucosal irritation or ulceration (Herlofson and Barkvoll, 1994; Scully et al., 1999; Kuttan et al., 2001). Application of cocaine may produce similar lesions (Parry et al., 1996).

(b) Drug-related aphthous-like ulceration
Sodium lauryl sulfate may predispose to ulcers similar to aphthous ulceration (Herlofson and Barkvoll, 1994). There are also case reports of aphthous-like ulceration arising following the use of beta-blockers such as labetalol (Pradalier et al., 1982), alendronate (Gonzalez-Moles and Bagan-Sebastian, 2000), captopril (Seedat, 1979; Nicholls et al., 1981; Corone et al., 1987; Montoner et al., 1990), nicorandil (Boulinguez et al., 1997; Reichart, 1997; Agbo-Godeau et al., 1998; Cribier et al., 1998; Desruelles et al., 1998; Roussel et al., 1998; Marquart-Elbaz et al., 1999; Shotts et al., 1999), some non-steroidal anti-inflammatory drugs (NSAIDs) (Siegel and Balciunas, 1991; Healy and Thornhill, 1995), mycophenolate or sirolimus (van Gelder et al., 2003), protease inhibitors (Scully and Diz, 2001), tacrolimus (Hernandez et al., 2001), and sulfonamides, though the exact pathogenic mechanisms are unclear in all of these.

A case-control study has now confirmed the associations of oral ulceration with NSAIDs and beta-blockers (Boulinguez et al., 2000) (Fig. 2).

View larger version (106K): [in this window] [in a new window]   Figure 2. NSAID-induced ulceration.

(d) Drug-related mucositis
Cytotoxic drugs are very commonly associated with mucositis and ulceration, which arises consistently with many chemotherapy regimens (Table 6), particularly those involving methotrexate, 5-fluorouracil, doxorubicine, melphelan, mercaptopurine, or bleomycin (Femiano et al., 2003). Such reactions can be so severe as to be treatment-limiting on occasion (Bell et al., 2001). Widespread sloughing and ulceration arise within days of commencement of therapy, the associated pain often requiring opioid therapy and/or alteration or cessation of chemotherapy. The ulceration may be a portal of entry for infection and hence a potential cause of septicemia. Drugs such as phenylbutazone that can cause agranulocytosis may also induce oral ulceration (Fig. 3).

View larger version (107K): [in this window] [in a new window]   Figure 3. Phenylbutazone-induced ulceration.

(e) Drug-related neoplasms and potentially malignant lesions
There is an increased prevalence of dysplastic and malignant lip lesions in immunosuppressed renal-transplant recipients (King et al., 1995) and liver transplant recipients (Haagsma et al., 2001). Oral leukoplakia has progressed rapidly to squamous cell carcinoma in some immunosuppressed patients (Hernandez et al., 2003), and oral squamous cell carcinoma has been reported in immunosuppressed patients without any recorded precursor lesion (Varga and Tyldesley, 1991).

Post-transplant lymphoproliferative disease (Raut et al., 2000), non-Hodgkin’s or MALT lymphoma (Hsi et al., 2000), usually manifesting as ulceration of the gingivae, fauces, or palate (Bilinska-Pietraszek et al., 2001; Mandel et al., 2001), or, rarely, Kaposi’s sarcoma (Meyers et al., 1976; Qunibi et al., 1988) may be complications of long-term immunosuppressive therapy, and there have even been reports of the resolution of malignancies where immunosuppression has been reduced (Keogh et al., 2002).

(f) Drug-related pemphigoid-like reactions and other bullous disorders
At least 30 drugs can give rise to conditions resembling bullous or mucous membrane pemphigoid (Vassileva, 1998) (Table 7). These drugs belong to a variety of pharmacological (thiol and non-thiol) and therapeutically targeted groups, including ACE inhibitors, furosemide, NSAIDs, penicillamine, psoralens, sulphonamides, cardioactive agents, and penicillin-related antibiotics. The oral mucosa is frequently affected in drug-induced pemphigoid, particularly penicillamine-induced disease, and can be the only affected mucosal surface, although patients often also have cutaneous lesions (Troy et al., 1981; Shuttleworth et al., 1985; Velthuis et al., 1985; Gall et al., 1986; Rasmussen et al., 1989). Other than the high frequency of oral mucosal lesions, the only other clinically distinguishing features of drug-induced pemphigoid are the younger age of affected patients compared with idiopathic (autoimmune) pemphigoid, and the resolution of disease following withdrawal of the causative agent.

Linear IgA disease (LAD) can be drug-induced, and affected patients have IgA antibodies to bullous-pemphigoid-associated antigen 1 (BPAG or BP1) or other antigens (Palmer et al., 2001). LAD is especially commonly induced by vancomycin (Kuechle et al., 1994), but other drugs such as angiotensin-converting enzyme inhibitors may be involved (Femiano et al., 2003).

(g) Drug-related pemphigus
Drug-induced pemphigus is not uncommon (Brenner et al., 1997). Traditionally, drugs that are capable of inducing pemphigus are divided into two main groups according to their chemical structure—drugs containing a sulfhydryl radical (thiol drugs or SH drugs) and non-thiol or other drugs, the latter often sharing an active amide group in their molecules (Wolf and Brenner, 1994).

Pemphigus vulgaris may occasionally be associated with drugs with active thiol groups in the molecule (Scully and Challacombe, 2002). Drugs implicated include penicillamine (Wolf et al., 1991; Laskaris and Satriano, 1993; Shapiro et al., 2000), phenol drugs (Goldberg et al., 1999), rifampicin (Gange et al., 1976), diclofenac (Matz et al., 1997), and, rarely, captopril (Korman et al., 1991), other ACE-inhibitors (Kaplan et al., 1992; Ong et al., 2000), and other drugs (Table 8).

The role of diet in the etiology of pemphigus is reviewed elsewhere (Brenner et al., 1998; Tur and Brenner, 1998), but garlic in particular may cause occasional cases of pemphigus (Laskaris and Nicolis, 1980; Korman et al., 1991; Ruocco et al., 1996).

(h) Drug-related erythema multiforme
A wide range of drugs—especially barbiturates, cephalosporins, NSAIDs, estrogens, phenothiazines, progestogens, protease inhibitors, sulphonamides, sulphonylurea derivatives, and tetracyclines—may give rise to erythema multiforme (Table 9), and it may be clinically impossible to distinguish drug-induced erythema multiforme from disease due to other causes (Roujeau, 1997; Ayangco and Rogers, 2003). The distinction of severe erythema multiforme from toxic epidermal necrolysis is quite unclear.

(i) Drug-related toxic epidermal necrolysis
Toxic epidermal necrolysis (TEN; Lyell syndrome) is clinically characterized by extensive mucocutaneous epidermolysis preceded by a macular or maculopapular exanthema and enanthema (Lyell, 1979; Rasmussen et al., 1989). Intra-orally, there is widespread painful blistering and ulceration of all mucosal surfaces. Toxic epidermolysis may be associated with antimicrobials (sulphonamides, thiacetazone), analgesics (phenazones). anti-epileptics, allopurinol, chlormezanone, rifampicin, fluconazole, and vancomycin (Ayangco and Rogers, 2003).

(j) Drug-related lupus-like disorders
Systemic lupus erythematosus (SLE) may be induced by a wide variety of different drugs. Indeed, over 70 agents have been implicated in causing drug-induced lupus (Rich, 1996) (Table 10). The most commonly implicated agents of drug-induced SLE are procainamide and hydralazine, although drugs less commonly associated include chlorpromazine, isoniazid, methyldopa, penicillamine, and quinine, as well as whole groups of drugs such as anticonvulsants, beta-blockers, sulphonamides, and others (Price and Venables, 1995).

(2) DRUG-RELATED WHITE LESIONS
(a) Burns (see above)
(b) Lichenoid eruptions
Since the advent of antimalarial therapy, there have been an ever-increasing list and spectrum of drugs that may give rise to mucocutaneous lichen planus (LP)-like eruptions (lichenoid reactions) (McCartan and McCreary, 1997; Scully et al., 1998). However, many of the reports claiming associations have been single case reports, and many of the drugs implicated in cutaneous lichenoid reactions have not been shown to be associated with oral lesions.

The possible association of drugs with lichenoid reactions was noted when quinacrine and mepacrine, used as antimalarials during World War II, were seen to cause lichenoid lesions. Apart from these drugs, gold was probably the most common agent recognized as initiating a lichenoid reaction (Penneys et al., 1974). Gold salts can cause a range of mucocutaneous lesions (Hakala et al., 1986) of which oral lichenoid lesions may be the first (Brown et al., 1993; Laeijendecker and van Joost, 1994).

The drugs now most commonly implicated in lichenoid reactions are the non-steroidal anti-inflammatory drugs and the angiotensin-converting enzyme inhibitors (Potts et al., 1987; Firth and Reade, 1989; Robertson and Wray, 1992; Van Dis and Parks, 1995). Lichenoid reactions also may follow the use of HIV protease inhibitors (Scully and Diz, 2001), antihypertensive agents, antimalarials, phenothiazines, sulphonamides, tetracyclines, thiazide diuretics, and many others (Table 11) (Dinsdale and Walker, 1966; Roberts and Marks, 1981; Chau et al., 1984; Hogan et al., 1985; Colvard et al., 1986; Markitziu et al., 1986;Torrelo et al., 1990), but the list of drugs implicated lengthens almost weekly and, interestingly, includes several agents which have also been used in the therapy of lichen planus, particularly dapsone (Downham, 1978), levamisole (Kirby et al., 1980), tetracycline (Mahboob and Haroon, 1998), and interferon (see below). Occasionally, there are lichenoid reactions to multiple drugs (Wiesenfeld et al., 1982).

The exact pathogenic mechanism by which drugs may cause LP-like disease are not known. Some of the agents implicated (e.g., penicillamine, captopril, and gold sodium thionalate) are thiol-like and hence implicated in pemphigus-like disease (see below). However, in LP, quite different immunological mechanisms are involved. It is likely that Grinspan’s syndrome simply represents a drug-induced disorder (Lamey et al., 1990), and drug therapy may occasionally account for the co-occurrence of LP with lupus erythematosus or bullous-like disease (Flageul et al., 1986). Clinical identification of lichenoid drug reactions has been based largely on subjective criteria: There does seem to be sometimes a tendency for these oral lesions to be unilateral (Lamey et al., 1995a) and erosive (Potts et al., 1987), but these features are by no means invariable. Histology may help; lichenoid lesions may have a more diffuse lymphocytic infiltrate and contain eosinophils and plasma cells, and there may be more colloid bodies than in classic LP, but there are no specific features (Van der Haute et al., 1989), and immunostaining is usually non-contributory, though basal cell cytoplasmic antibodies may be found (Lamey et al., 1995b), but this has not been confirmed (Ingafou et al., 1997) and surely occurs less reliably than in cutaneous drug reactions (van Joost, 1974; McQueen and Behan, 1982; Gibson et al., 1986).

The most reliable means to diagnose lichenoid reactions is if the reaction remits with drug withdrawal and returns on rechallenge, but frequently this is not possible because of the need to ensure patient safety.

Dental restorative materials may also be associated with lichenoid lesions. Most patients with OLP have no evidence of any association with dental restorative materials (Hietanen et al., 1987). However, contact with or proximity to restorations involving amalgams or other materials causes some lichenoid reactions—that is, lesions that clinically and histologically resemble LP closely, but have an identifiable etiology (Lind et al., 1986; Bolewska et al., 1990). These reactions are presumably due to allergic or toxic reactions to compounds released or generated, the Koebner phenomenon, or possibly due to plaque accumulated on the surfaces of the restorations (Holmstrup, 1991).

Some of these oral lesions may improve after substitution of the amalgam by other materials (Finne et al., 1982; Jolly et al., 1986; Lind et al., 1986; Bolewska et al., 1990; Jameson et al., 1990; Skoglund and Egelrud, 1991; Laine et al., 1992; Bircher et al., 1993; Ostman et al., 1994; Henriksson et al., 1995; Smart et al., 1995; Bratel et al., 1996; Ibbotson et al., 1996), though this is often not the case with gingival lesions (Henriksson et al., 1995).

Significant reactions to mercuric salts on skin-testing may be seen in some patients with OLP (Finne et al., 1982; Eversole and Ringer, 1984; Mobacken et al., 1984; James et al., 1987; Ostman et al., 1994), though others have not found this (Hietanen et al., 1987). Finne et al.(1982) demonstrated mercury sensitivity by patch-testing in 62% of 29 patients with OLP and only 3.2% of a control group, and in a few patients their oral lesions regressed on removal of the amalgams (Finne et al., 1982). Reactions to mercuric chloride have been reported (Skoglund and Egelrud, 1991; Smart et al., 1995). These findings have been supported, and recently in studies by Skoglund and co-workers (Ostman et al., 1994), a patch-test positivity against mercury was found in 39.6% of 48 patients. Of those who had a positive patch test to mercury, 94.7% showed regression of lesions after removal of amalgams, but even 82.6% of those who showed no reaction to mercury on patch-testing also showed regression after removal of amalgams. Epicutaneous patch tests are of little prognostic value (Ostman et al., 1994; Ibbotson et al., 1996). Oral mucosal lesions of lichenoid character might not be associated with allergy to mercury, but with mechanical or galvanic insults; their interpretation calls for intra-oral patch-testing (Axéll et al., 1986).

There may also be occasional reactions to gold restorations (Conklin and Blasberg, 1987), although this has not been substantiated. There is also a report of OLP in relation to cobalt in a restoration (Torresani et al., 1994).

Composite restorations have also been implicated in oral lichenoid reactions (Lind and Hurlen, 1988), and so the wholesale replacement of amalgams as a possible treatment is not necessarily warranted.

(c) Lupoid reactions (see above)
(d) Candidosis
Pseudomembranous candidosis arises secondary to therapy with broad-spectrum antibiotics (Scully et al., 1994), corticosteroids (both systemic and inhaler preparations), and other immunosuppressive regimens (e.g., ciclosporin) and cytotoxic therapies (Table 12). More rarely, mucormycosis and aspergillosis may cause thrush-like areas or other lesions in patients on long-term immunosuppressive therapies (Dreizen et al., 1992; Scully, 1992; Seymour et al., 1997).

(f) Hairy leukoplakia
Oral hairy leukoplakia, usually affecting the dorsum and lateral borders of the tongue and floor of mouth, may be a consequence of Epstein-Barr virus infection, associated with therapy with corticosteroids (topical and systemic), ciclosporin, or other long-term immunosuppressive regimens (Triantos et al., 1997).

(g) Leukoplakia
Tobacco and alcohol use are important risk factors for leukoplakia (Pindborg et al., 1980; Sciubba, 1995) and oral epithelial dysplasia (Jaber et al., 1998). An increased frequency of lesions with epithelial dysplasia of the lips (but not oral mucosa) has been observed in some but not all iatrogenically immunosuppressed patients (King et al., 1995; Seymour et al., 1997).

Sanguinarine, the principal alkaloid of the bloodroot plant (Sanguinaria canadensis), which is used in some mouthwashes and dentifrices for its anti-plaque activity, may be associated with the development of oral leukoplakia (Damm et al., 1999; Allen et al., 2001; Mascarenhas et al., 2001, 2002).

	Drug-related Mucosal Pigmentation

TOP Previous Next

 
(1) DRUG-RELATED SUPERFICIAL TRANSIENT DISCOLORATION
Superficial transient discoloration of the dorsum of the tongue and other soft tissues and teeth may be of various colors, typically yellowish or brown, and may be caused by some foods and beverages (such as coffee and tea), some habits (such as tobacco, betel, and crack cocaine use) (Mirbod and Ahing, 2000), and some drugs (such as iron salts, bismuth, chlorhexidine, or antibiotics), especially if these also induce xerostomia (such as psychotropic agents) (Ramadan, 1969; Suzuki et al., 1983; Ogunwande, 1989; Heymann, 2000) (Table 13). When such discoloration noticeably affects the posterior dorsum of the tongue, and the filiform papillae are excessively long and stained dark brown or black, the term ‘black hairy tongue’ is used, but this is less common than other superficial discolorations.

(2) DRUG-RELATED INTRINSIC PIGMENTATION
Localized areas of pigmentation of the mucosa may be due to amalgam, while gingival pigmentation can arise secondary to the gold or metal alloys of crowns (Kedici et al., 1995). Heavy metal salts were previously reported to cause pigmentation, particularly of the gingival margin (Tables 13, 14).

Minocycline has increasingly been reported to cause widespread blue, blue-grey, or brown pigmentation of the gingivae and mucosae. While much of this pigmentation may reflect discoloration of the underlying bone and roots of teeth, there is also inherent pigmentation of the oral mucosa, including the tongue (Meyerson et al., 1995; Westbury and Najera, 1997).

Oral contraceptives may, albeit rarely, cause melanotic pigmentation (Hertz et al., 1980), as can cyclophosphamide, busulphan, and ACTH (Scully and Porter, 1997). In HIV disease, drug-induced melanotic pigmentation may arise following therapy with clofazimine zidovudine and/or ketoconazole, the pigmentation being variably diffuse or macular-like (Ficarra et al., 1990; Porter et al., 1990).

Kaposi’s sarcoma of the mouth is a rare complication of immunosuppression, manifesting as a blue, red, or purple macule, papule, nodule, or area of ulceration, typically on the palate or gingivae, but able to affect other oral mucosal sites (see above).

	Drug-related Swellings

TOP Previous Next

 
(1) DRUG-RELATED GINGIVAL ENLARGEMENT
Gingival enlargement is a well-described oral side-effect of drug therapy (Marshall and Bartold, 1998) (Table 15). The drugs most commonly implicated in causing this enlargement are phenytoin (Seymour and Jacobs, 1992), ciclosporin (Seymour and Jacobs, 1992a), and the calcium-channel-blockers nifedipine (Fattore et al., 1991), diltiazem (Bowman et al., 1988), verapamil (Pernu et al., 1989), and amlodipine (Ellis et al., 1993). Patients receiving therapy with both ciclosporin and calcium-channel-blockers (e.g., post-cardiac or -renal allograft recipients) may be sometimes, but not always, particularly liable to drug-induced gingival enlargement.

Rarely, Kaposi’s sarcoma (Qunibi et al., 1988) or squamous cell carcinoma (Varga and Tyldesley, 1991) may arise within areas of ciclosporin-induced gingival enlargement.

Other drugs that have been occasionally reported to cause gingival enlargement include erythromycin (Valsecchi and Cainelli, 1992), sodium valproate (Syrjanen and Syrjanen, 1979), phenobarbitone (Gregoriou et al., 1996), and vigabatrin (Katz et al., 1997), but these have all been isolated reports.

(2) DRUG-RELATED LIP AND MUCOSAL SWELLING
Drug-induced mucosal swelling predominantly affects the lips and tongue (although rare isolated swelling of the uvula [Quinke’s disease] can occur [Mattingly et al., 1993]), and is typically due to type I hypersensitivity reactions. The oral and dental aspects of hypersensitivity are reviewed elsewhere (Rees and Gibson, 1997), but a range of drugs—particularly penicillins, local anesthetic agents, cephalosporin derivatives, angiotensin-converting enzyme inhibitors, aspirin, and barbiturates—may give rise to angio-edema (Table 16). Hypersensitivity to latex is an increasing problem in oral health care and may cause rapid-onset angio-edema in susceptible patients.

Plasmacytosis due to ‘tartar control’ toothpastes gives rise to localized enlargements of the gingivae, tongue, and other oral mucosae. This disorder is histopathologically characterized by a polyclonal plasmacytic infiltrate of the upper lamina propria and may rarely affect other mucosal surfaces, such as the larynx and anogenital surfaces (White et al., 1986; Timms et al., 1988).

	Drug-related Cheilitis

TOP Previous Next

 
Cheilitis is commonly caused by contact reactions to cosmetics or foods, but drugs may also be implicated, particularly cytotoxic agents, phenothiazines, protease inhibitors, psoralens, and retinoids (Scully et al., 2000) (Table 17).

	Drug-related Neuropathies

TOP Previous Next

	Drug-related Oral Malodor (Halitosis)

TOP Previous Next

	Drug-related Tooth Discoloration

TOP Previous Next

	Summary

TOP Previous Next

There are few relevant randomized double-blind controlled studies in this field, and the only data available are from case reports, small series, and non-peer-reviewed reports of adverse drug reactions.

The clinician should take a careful drug history and always exclude drugs as a cause of oral and peri-oral symptoms and signs.

REFERENCES

TOP

• Abdollahi M, Radfar M (2003). A review of drug-induced oral reactions. J Contemp Dent Pract 4:10–31.[Medline] [Order article via Infotrieve]
• Ackerman BH, Kasbekar N (1997). Disturbances of taste and smell induced by drugs. Pharmacotherapy 17:482–496.[Medline] [Order article via Infotrieve]
• Adams CE, Eisenbruch M (2000). Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev 2:CD000307.
• Agbo-Godeau S, Joly P, Lauret P, Szpirglas R, Szpirglas H (1998). Association of major aphthous ulcers and nicorandil. Lancet 352:1598–1599.[CrossRef][Medline] [Order article via Infotrieve]
• Allen CL, Loudon J, Mascarenhas AK (2001). Sanguinaria-related leukoplakia: epidemiologic and clinicopathologic features of a recently described entity. Gen Dent 49:608–614.[Medline] [Order article via Infotrieve]
• Anttila SA, Leinonen EV (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:249–264.[Medline] [Order article via Infotrieve]
• Atkinson JC, Shiroky JB, Macynski A, Fox PC (1989). Effects of furosemide on the oral cavity. Gerodontology 8:23–26.[Medline] [Order article via Infotrieve]
• Axéll T, Spiechowicz E, Glantz PO, Andersson G, Larsson A (1986). A new method for intraoral patch testing. Contact Dermatitis 15:58–62.[Medline] [Order article via Infotrieve]
• Ayangco L, Rogers RS III (2003). Oral manifestations of erythema multiforme. Dermatol Clin 21:195–205.[CrossRef][Medline] [Order article via Infotrieve]
• Bell KA, Perna AG, Hsu S (2001). Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 45:790–791.[CrossRef][Medline] [Order article via Infotrieve]
• Bergdahl M, Bergdahl J (2000). Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 79:1652–1658.[Abstract/Free Full Text]
• Bilinska-Pietraszek E, Namyslowski G, Mrowka-Kata K, Scierski W, Aniol-Borkowska M (2001). [A case of tongue neoplasm in a 15-year old patient treated with immunosuppressants for renal insufficiency]. Otolaryngol Pol 55:95–97.[Medline] [Order article via Infotrieve]
• Bircher AJ, von Schulthess A, Henning G (1993). Oral lichenoid lesions and mercury sensitivity. Contact Dermatitis 29:275–276.[CrossRef][Medline] [Order article via Infotrieve]
• Bolewska J, Hansen HJ, Holmstrup P, Pindborg JJ, Stangerup M (1990). Oral mucosal lesions related to silver amalgam restorations. Oral Surg Oral Med Oral Pathol 70:55–58.[CrossRef][Medline] [Order article via Infotrieve]
• Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et al. (2002). Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 26:593–604.[CrossRef][Medline] [Order article via Infotrieve]
• Bosch JA, Valdes M, Oristrell J, Pigrau C, Ordi J (1985). Oxyphenbutazone-induced sialadenitis, intrahepatic cholestasis and pancreatitis. Acta Gastroenterol Belg 48:529–530.[Medline] [Order article via Infotrieve]
• Boulinguez S, Bedane C, Bouyssou-Gauthier ML, Cornee-Leplat I, Truong E, Bonnetblanc JM (1997). [Giant buccal aphthosis caused by nicorandil]. Presse Med 26(12):558.[Medline] [Order article via Infotrieve]
• Boulinguez S, Reix S, Bedane C, Debrock C, Bouyssou-Gauthier ML, Sparsa A, et al. (2000). Role of drug exposure in aphthous ulcers: a case-control study. Br J Dermatol 143:1261–1265.[Medline] [Order article via Infotrieve]
• Bowman JM, Levy BA, Grubb RV (1988). Gingival overgrowth induced by diltiazem. A case report. Oral Surg Oral Med Oral Pathol 65:183–185.[CrossRef][Medline] [Order article via Infotrieve]
• Boyd LD, Dwyer JT, Papas A (1997). Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. Nutr Rev 55:362–368.[Medline] [Order article via Infotrieve]
• Bratel J, Hakeberg M, Jontell M (1996). Effect of replacement of dental amalgam on oral lichenoid reactions. J Dent 24:41–45.[Medline] [Order article via Infotrieve]
• Bray GA (2001). Drug treatment of obesity. Rev Endocr Metab Disord 2:403–418.[Medline] [Order article via Infotrieve]
• Brenner S, Bialy-Golan A, Anhalt GJ (1997). Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 36:919–923.[CrossRef][Medline] [Order article via Infotrieve]
• Brenner S, Bialy-Golan A, Ruocco V (1998). Drug-induced pemphigus. Clin Dermatol 16:393–397.[CrossRef][Medline] [Order article via Infotrieve]
• British National Formulary (2002). Antituberculous drugs. In: British National Forumulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, pp. 290–291.
• Brown RS, Hays GL, Flaitz CM (1993). Treatment of gold salt-induced oral lichen planus: report of a case. Cutis 51:183–185.[Medline] [Order article via Infotrieve]
• Bruera E, Belzile M, Neumann CM, Ford I, Harsanyi Z, Darke A (1999). Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial. Support Care Cancer 7:280–283.[Medline] [Order article via Infotrieve]
• Bucknall CA, Keeton BR, Curry PV, Tynan MJ, Sutherland GR, Holt DW (1986). Intravenous and oral amiodarone for arrhythmias in children. Br Heart J 56:278–284.[Abstract/Free Full Text]
• Burlingame RW, Rubin RL (1996). Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol Biol Rep 23:159–166.[CrossRef][Medline] [Order article via Infotrieve]
• Busto UE, Sproule BA, Knight K, Herrmann N (2001). Use of prescription and nonprescription hypnotics in a Canadian elderly population. Can J Clin Pharmacol 8:213–221.[Medline] [Order article via Infotrieve]
• Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr (2000). The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118:1294–1302.
• Cebeci I, Kantarci A, Firatli E, Carin M, Tuncer O (1996). The effect of verapamil on the prevalence and severity of cyclosporine-induced gingival overgrowth in renal allograft recipients. J Periodontol 67:1201–1205.[Medline] [Order article via Infotrieve]
• Chacko RC, Marsh BJ, Marmion J, Dworkin RJ, Telschow R (1987). Lithium side effects in elderly bipolar outpatients. Hillside J Clin Psychiatry 9:79–88.[Medline] [Order article via Infotrieve]
• Chau NY, Reade PC, Rich AM, Hay KD (1984). Allopurinol-amplified lichenoid reactions of the oral mucosa. Oral Surg Oral Med Oral Pathol 58:397–400.[Medline] [Order article via Infotrieve]
• Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, et al. (2001). Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60:110–115.[CrossRef][Medline] [Order article via Infotrieve]
• Chimenes H (1971). [Phenylbutazone derivatives and pathology of the salivary glands]. Presse Med 79(2):54.[Medline] [Order article via Infotrieve]
• Christodoulou GN, Siafakas A, Rinieris PM (1977). Side-effects of lithium. Acta Psychiatr Belg 77:260–266.[Medline] [Order article via Infotrieve]
• Clemett D, Jarvis B (2001). Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18:277–304.[CrossRef][Medline] [Order article via Infotrieve]
• Cohen L, Banks P (1966). Salivary gland enlargement and phenylbutazone. Br Med J 5500:1420.
• Colvard MD, Nadimi H, Gargiulo AV (1986). Ativan (lorazepam) induced lichenoid reaction of the human attached gingiva: case report. Periodontal Case Rep 8:69–70.[Medline] [Order article via Infotrieve]
• Comley C, Galletly C, Ash D (2000). Use of atropine eye drops for clozapine induced hypersalivation. Aust NZ J Psychiatry 34:1033–1034.[CrossRef][Medline] [Order article via Infotrieve]
• Conklin RJ, Blasberg B (1987). Oral lichen planus. Dermatol Clin 5:663–673.[Medline] [Order article via Infotrieve]
• Consroe P, Sandyk R, Snider SR (1986). Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277–282.[Medline] [Order article via Infotrieve]
• Conti L, Pinder RM (1979). A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric out-patients. J Int Med Res 7:285–289.[Medline] [Order article via Infotrieve]
• Corone S, Davido A, Corone P (1987). [A rare complication of captopril: ulceration of the lingual and jugal mucosae]. Rev Med Interne 8:73–74.[Medline] [Order article via Infotrieve]
• Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr (2000). Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 7:211–217.[CrossRef][Medline] [Order article via Infotrieve]
• Cribier B, Marquart-Elbaz C, Lipsker D, Alt M, Grosshans E (1998). Chronic buccal ulceration induced by nicorandil. Br J Dermatol 138:372–373.[CrossRef][Medline] [Order article via Infotrieve]
• Damm DD, Curran A, White DK, Drummond JF (1999). Leukoplakia of the maxillary vestibule—an association with Viadent? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87:61–66.[CrossRef][Medline] [Order article via Infotrieve]
• Davies AN, Broadley K, Beighton D (2001). Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22:820–825.[Medline] [Order article via Infotrieve]
• Davis R, Faulds D (1996). Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 52:696–724.[Medline] [Order article via Infotrieve]
• Desruelles F, Bahadoran P, Lacour JP, Perrin C, Santini J, Ortonne JP (1998). Giant oral aphthous ulcers induced by nicorandil. Br J Dermatol 138:712–713.[CrossRef][Medline] [Order article via Infotrieve]
• Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308–315.[Medline] [Order article via Infotrieve]
• Di Giovanni J (1990). Drugs and the geriatric patient: a review of problems and special considerations faced by the dentist. Spec Care Dentist 10:161–163.[Medline] [Order article via Infotrieve]
• Dickstein K, Manhenke C, Aarsland T, McNay J, Wiltse C, Wright T (2000). The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. Int J Cardiol 75:167–176.[CrossRef][Medline] [Order article via Infotrieve]
• Diederich NJ, Goetz CG (1998). Drug-induced movement disorders. Neurol Clin 16:125–139.[Medline] [Order article via Infotrieve]
• Dinsdale RC, Walker AE (1966). Amiphenazole sensitivity with oral ulceration. Br Dent J 121:460–462.[Medline] [Order article via Infotrieve]
• Dodd CL, Greenspan D, Westenhouse JL, Katz MH (1992). Xerostomia associated with didanosine. Lancet 340(8822):790.[Medline] [Order article via Infotrieve]
• Dolberg OT, Klag E, Gross Y, Schreiber S (2002). Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl) 161:404–407.[Medline] [Order article via Infotrieve]
• Downham TF III (1978). Spironolactone-induced lichen planus. J Am Med Assoc 240(11):1138.[Abstract/Free Full Text]
• Dreizen S, Keating MJ, Beran M (1992). Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. Postgrad Med 91:349–357.[Medline] [Order article via Infotrieve]
• Duggan L, Fenton M, Dardennes RM, El Dosoky A, Indran S (2000). Olanzapine for schizophrenia. Cochrane Database Syst Rev (2):CD001359.
• Ebo DG, Stevens WJ (1997). Angioedema of ACE inhibitors. Allergy 52:354–355.[Medline] [Order article via Infotrieve]
• Eisen D (1993). Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol 28:609–612.[Medline] [Order article via Infotrieve]
• Elie R, Lamontagne Y (1984). Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 4:125–129.[Medline] [Order article via Infotrieve]
• Ellingrod VL, Perry PJ (1994). Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 51:3033–3046.[Abstract]
• Ellis JS, Seymour RA, Thomason JM, Monkman SC, Idle JR (1993). Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 341:1102–1103.[Medline] [Order article via Infotrieve]
• Eversole LR, Ringer M (1984). The role of dental restorative metals in the pathogenesis of oral lichen planus. Oral Surg Oral Med Oral Pathol 57:383–387.[Medline] [Order article via Infotrieve]
• Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M, Doherty-Greenberg JM (1991). Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist 11:107–109.[Medline] [Order article via Infotrieve]
• Feighner JP (1999). Mechanism of action of antidepressant medications. J Clin Psychiatry 60(Suppl 4):4–11.
• Feighner JP, Overo K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 60:824–830.[Medline] [Order article via Infotrieve]
• Femiano F, Scully C, Gombos F (2002). Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy. Int J Oral Maxillofac Surg 31:625–628.[CrossRef][Medline] [Order article via Infotrieve]
• Femiano F, Scully C, Gombos F (2003). Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:169–173.[Medline] [Order article via Infotrieve]
• Ficarra G, Shillitoe EJ, Adler-Storthz K, Gaglioti D, Di Pietro M, Riccardi R, et al. (1990). Oral melanotic macules in patients infected with human immunodeficiency virus. Oral Surg Oral Med Oral Pathol 70:748–755.[Medline] [Order article via Infotrieve]
• Field EA, Fear S, Higham SM, Ireland RS, Rostron J, Willetts RM, et al. (2001). Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice. Gerodontology 18:21–24.[CrossRef][Medline] [Order article via Infotrieve]
• Finne K, Goransson K, Winckler L (1982). Oral lichen planus and contact allergy to mercury. Int J Oral Surg 11:236–239.[Medline] [Order article via Infotrieve]
• Firth NA, Reade PC (1989). Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 67:41–44.[CrossRef][Medline] [Order article via Infotrieve]
• Flageul B, Foldes C, Wallach D, Vignon-Pennamen MD, Cottenot F (1986). Captopril-induced lichen planus pemphigoides with pemphigus-like features. A case report. Dermatologica 173:248–255.[Medline] [Order article via Infotrieve]
• Ford B, Greene P, Fahn S (1994). Oral and genital tardive pain syndromes. Neurology 44:2115–2119.[Abstract/Free Full Text]
• Fox PC (1998). Acquired salivary dysfunction. Drugs and radiation. Ann NY Acad Sci 842:132–137.[CrossRef][Medline] [Order article via Infotrieve]
• Freye E, Baranowski J, Latasch L (2001). Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers. Arzneimittelforschung 51:60–66.[Medline] [Order article via Infotrieve]
• Friedlander AH, Birch NJ (1990). Dental conditions in patients with bipolar disorder on long-term lithium maintenance therapy. Spec Care Dentist 10:148–151.[Medline] [Order article via Infotrieve]
• Gabb GM, Ryan P, Wing LM, Hutchinson KA (1996). Epidemiological study of angioedema and ACE inhibitors. Aust NZ J Med 26:777–782.[Medline] [Order article via Infotrieve]
• Gall Y, Guillet G, Leroy JP, Masse R, Guillet MH (1986). [Bullae and urticaria-like lesions of allergic vasculitis with immunomarkers of the bullous pemphigoid type during treatment with D-penicillamine]. Ann Dermatol Venereol 113:55–58.[Medline] [Order article via Infotrieve]
• Gange RW, Rhodes EL, Edwards CO, Powell ME (1976). Pemphigus induced by rifampicin. Br J Dermatol 95:445–448.[CrossRef][Medline] [Order article via Infotrieve]
• Gattoni F, Pozzato C, Padovese P, Rizzi AM, Brancaccio D, Uslenghi C (1991). [Salivary gland enlargement caused by intravenous iodinated contrast medium. Description of a case]. Radiol Med (Torino) 81:162–163.
• Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. J Am Med Assoc 283:3082–3088.[Abstract/Free Full Text]
• Giansanti JS, Tillery DE, Olansky S (1971). Oral mucosal pigmentation resulting from antimalarial therapy. Oral Surg Oral Med Oral Pathol 31:66–69.[Medline] [Order article via Infotrieve]
• Gibson LE, van Hale HM, Schroeter AL (1986). Direct immunofluorescence for the study of cutaneous drug eruptions. Acta Derm Venereol 66:39–44.[Medline] [Order article via Infotrieve]
• Glass BJ (1989). Drug-induced xerostomia as a cause of glossodynia. Ear Nose Throat J 68(10):776–781.[Medline] [Order article via Infotrieve]
• Glover J, Dibble S, Miaskowski C, Geibert R (1995). Changes in taste associated with intravenous administration of pentamidine. J Assoc Nurses AIDS Care 6:43–48.[Medline] [Order article via Infotrieve]
• Goldberg I, Kashman Y, Brenner S (1999). The induction of pemphigus by phenol drugs. Int J Dermatol 38:888–892.[CrossRef][Medline] [Order article via Infotrieve]
• Gonzalez-Moles MA, Bagan-Sebastian JV (2000). Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29:514–518.[CrossRef][Medline] [Order article via Infotrieve]
• Goodman GE, Alberts DS, Earnst DL, Meyskens FL (1983). Phase I trial of retinol in cancer patients. J Clin Oncol 1:394–399.[Abstract]
• Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A (2001). The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 15:167–172.[Abstract/Free Full Text]
• Greco S, Mazzaglia G, Caputi AP, Pagliaro L (1997). Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. Ann Pharmacother 31:1548.[Medline] [Order article via Infotrieve]
• Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S (1987). A comparative study of herpes simplex infections in renal transplant and leukemic patients. J Infect Dis 156:280–287.[Medline] [Order article via Infotrieve]
• Greenwood I, Heylen R, Zakrzewska JM (1998). Anti-retroviral drugs—implications for dental prescribing. Br Dent J 184:478–482.[Medline] [Order article via Infotrieve]
• Gregoriou AP, Schneider PE, Shaw PR (1996). Phenobarbital-induced gingival overgrowth? Report of two cases and complications in management. ASDC J Dent Child 63:408–413.[Medline] [Order article via Infotrieve]
• Griffin JP (1992). Drug-induced disorders of taste. Adverse Drug React Toxicol Rev 11:229–239.[Medline] [Order article via Infotrieve]
• Grotenhermen F (1999). [The effects of cannabis and THC]. Forsch Komplementarmed 6(Suppl 3):7–11.[Medline] [Order article via Infotrieve]
• Guasti L, Grimoldi P, Diolisi A, Petrozzino MR, Gaudio G, Grandi AM, et al. (1998). Treatment with enalapril modifies the pain perception pattern in hypertensive patients. Hypertension 31:1146–1150.[Abstract/Free Full Text]
• Gwaltney JM Jr, Park J, Paul RA, Edelman DA, O’Connor RR, Turner RB (1996). Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis 22:656–662.[Medline] [Order article via Infotrieve]
• Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. (2001). Increased cancer risk after liver transplantation: a population-based study. J Hepatol 34:84–91.[Medline] [Order article via Infotrieve]
• Haas DA, Lennon D (1995). A 21 year retrospective study of reports of paresthesia following local anesthetic administration. J Canad Dent Assoc 61:319–330.
• Hakala M, van Assendelft AH, Ilonen J, Jalava S, Tiilikainen A (1986). Association of different HLA antigens with various toxic effects of gold salts in rheumatoid arthritis. Ann Rheum Dis 45:177–182.[Abstract/Free Full Text]
• Halpern SM, Todd PM, Kirby JD (1996). Loss of taste associated with isotretinoin. Br J Dermatol 134:378.[Medline] [Order article via Infotrieve]
• Hansen TE, Casey DE, Hoffman WF (1997). Neuroleptic intolerance. Schizophr Bull 23:567–582.[Abstract/Free Full Text]
• Hatlebakk JG, Nesje LB, Hausken T, Bang CJ, Berstad A (1995). Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol 30:1053–1057.[Medline] [Order article via Infotrieve]
• Hay-Smith J, Herbison P, Ellis G, Moore K (2002). Anticholinergic drugs versus placebo for overactive bladder syndrome in adults (Cochrane Review). Cochrane Database Syst Rev (3):CD003781.
• Healy CM, Thornhill MH (1995). An association between recurrent oro-genital ulceration and non-steroidal anti-inflammatory drugs. J Oral Pathol Med 24:46–48.[CrossRef][Medline] [Order article via Infotrieve]
• Henkin RI (1994). Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Safety 11:318–327.[Medline] [Order article via Infotrieve]
• Hennes R, Mack A, Schell H, Vogt HJ (1984). 13-cis-retinoic acid in conglobate acne. A follow-up study of 14 trial centers. Arch Dermatol Res 276:209–215.[Medline] [Order article via Infotrieve]
• Henriksson E, Mattsson U, Hakansson J (1995). Healing of lichenoid reactions following removal of amalgam. A clinical follow-up. J Clin Periodontol 22:287–294.[Medline] [Order article via Infotrieve]
• Herlofson BB, Barkvoll P (1994). Sodium lauryl sulfate and recurrent aphthous ulcers. A preliminary study. Acta Odontol Scand 52:257–259.[Medline] [Order article via Infotrieve]
• Herman I, Schwartz Y, Bassan H (1974). [Primary cardiac involvement and painful salivary gland enlargement due to phenylbutazone]. Harefuah 86:246–247.[Medline] [Order article via Infotrieve]
• Hernandez G, Jimenez C, Arriba L, Moreno E, Lucas M (2001). Resolution of oral ulcerations after decreasing the dosage of tacrolimus in a liver transplantation recipient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:526–531.[Medline] [Order article via Infotrieve]
• Hernandez G, Arriba L, Jimenez C, Bagan JV, Rivera B, Lucas M, et al. (2003). Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient. Oral Oncol 39:87–90.[Medline] [Order article via Infotrieve]
• Hertz RS, Beckstead PC, Brown WJ (1980). Epithelial melanosis of the gingiva possibly resulting from the use of oral contraceptives. J Am Dent Assoc 100:713–714.[Abstract]
• Heymann WR (2000). Psychotropic agent-induced black hairy tongue. Cutis 66:25–26.[Medline] [Order article via Infotrieve]
• Hietanen J, Pihlman K, Forstrom L, Linder E, Reunala T (1987). No evidence of hypersensitivity to dental restorative metals in oral lichen planus. Scand J Dent Res 95:320–327.[Medline] [Order article via Infotrieve]
• Hogan DJ, Murphy F, Burgess WR, Epstein JD, Lane PR (1985). Lichenoid stomatitis associated with lithium carbonate. J Am Acad Dermatol 13:243–246.[Medline] [Order article via Infotrieve]
• Holmstrup P (1991). Reactions of the oral mucosa related to silver amalgam: a review. J Oral Pathol Med 20:1–7.[Medline] [Order article via Infotrieve]
• Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S (2000). Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 24:100–106.[CrossRef][Medline] [Order article via Infotrieve]
• Hunter KD, Wilson WS (1995). The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 40:983–989.[Medline] [Order article via Infotrieve]
• Ibbotson SH, Speight EL, Macleod RI, Smart ER, Lawrence CM (1996). The relevance and effect of amalgam replacement in subjects with oral lichenoid reactions. Br J Dermatol 134:420–423.[Medline] [Order article via Infotrieve]
• Ilia R, Aizenberg O, Moshe G (1991). Salivary gland enlargement following renografin injection may be secondary to hypersensitivity. Cathet Cardiovasc Diagn 23:69–70.[Medline] [Order article via Infotrieve]
• Ingafou M, Lodi G, Olsen I, Porter SR (1997). Oral lichen planus is not associated with IgG circulating antibodies to epithelial antigens. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:175–178.[Medline] [Order article via Infotrieve]
• Jaber MA, Porter SR, Scully C, Gilthorpe MS, Bedi R (1998). The role of alcohol in non-smokers and tobacco in non-drinkers in the aetiology of oral epithelial dysplasia. Int J Cancer 77:333–336.[Medline] [Order article via Infotrieve]
• Jackson C, Babich S (1997). Gingival hyperplasia: interaction between cyclosporin A and nifedipine? A case report. NY State Dent J 63:46–48.
• Jacquetin B, Wyndaele J (2001). Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98:97–102.[Medline] [Order article via Infotrieve]
• James J, Ferguson MM, Forsyth A, Tulloch N, Lamey PJ (1987). Oral lichenoid reactions related to mercury sensitivity. Br J Oral Maxillofac Surg 25:474–480.[Medline] [Order article via Infotrieve]
• Jameson MW, Kardos TB, Kirk EE, Ferguson MM (1990). Mucosal reactions to amalgam restorations. J Oral Rehabil 17:293–301.[Medline] [Order article via Infotrieve]
• Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA (1997). Drug-induced movement disorders. Drug Safety 16:180–204.[Medline] [Order article via Infotrieve]
• Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J (2001). Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 3:131–140.[Abstract]
• Jolly M, Moule AJ, Bryant RW, Freeman S (1986). Amalgam-related chronic ulceration of oral mucosa. Br Dent J 160:434–437.[Medline] [Order article via Infotrieve]
• Kaiser HB, Banov CH, Berkowitz RR, Bernstein DI, Bronsky EA, Georgitis JW, et al. (1998). Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther 5:245–251.[Medline] [Order article via Infotrieve]
• Kaplan RP, Potter TS, Fox JN (1992). Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 26:364–366.[Medline] [Order article via Infotrieve]
• Katz J, Givol N, Chaushu G, Taicher S, Shemer J (1997). Vigabatrin-induced gingival overgrowth. J Clin Periodontol 24:180–182.[CrossRef][Medline] [Order article via Infotrieve]
• Kaufman E, Garfunkel AA, Tzukert A (1977). [Acute sialadenitis due to butazolidin]. Harefuah 93:405–406.[Medline] [Order article via Infotrieve]
• Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, et al. (2001). Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol 13:915–919.[Medline] [Order article via Infotrieve]
• Kawaguchi M, Yamagishi H (1995). [Receptive systems for drugs in salivary gland cells]. Nippon Yakurigaku Zasshi 105:295–303.[Medline] [Order article via Infotrieve]
• Kedici PS, Memikoglu MM, Kansu G, Isimer A, Gunhan O (1995). Case report: ionisation tendency of a base metal alloy in the oral environment. Eur J Prosthodont Restor Dent 3:231–234.[Medline] [Order article via Infotrieve]
• Keogh PV, Fisher V, Flint SR (2002). Resolution of oral non-Hodgkin’s lymphoma by reduction of immunosuppressive therapy in a renal allograft recipient: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94:697–701.[Medline] [Order article via Infotrieve]
• King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, et al. (1995). Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 332:1052–1057.[Abstract/Free Full Text]
• Kirby JD, Black M, McGibbon D (1980). Levamisole-induced lichenoid eruptions. J R Soc Med 73:208–211.[Medline] [Order article via Infotrieve]
• Knulst AC, Stengs CJ, Baart DF, Graamans K, Hene RJ, Collet JT, et al. (1995). Salivary gland swelling following naproxen therapy. Br J Dermatol 133:647–649.[Medline] [Order article via Infotrieve]
• Korman NJ, Eyre RW, Zone J, Stanley JR (1991). Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 96:273–276.[CrossRef][Medline] [Order article via Infotrieve]
• Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS (1994). Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 30:187–192.[Medline] [Order article via Infotrieve]
• Kuttan NA, Narayana N, Moghadam BK (2001). Desquamative stomatitis associated with routine use of oral health care products. Gen Dent 49:596–602.[Medline] [Order article via Infotrieve]
• Lader MH (1996). Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 57(Suppl 2):39–44.[Medline] [Order article via Infotrieve]
• Laeijendecker R, van Joost T (1994). Oral manifestations of gold allergy. J Am Acad Dermatol 30:205–209.[Medline] [Order article via Infotrieve]
• Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J, et al. (2001). Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 70:327–335.[CrossRef][Medline] [Order article via Infotrieve]
• Laine P, Meurman JH, Tenovuo J, Murtomaa H, Lindqvist C, Pyrhonen S, et al. (1992). Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. Eur J Cancer B Oral Oncol 28(B):125–128.
• Lamey PJ, Gibson J, Barclay SC, Miller S (1990). Grinspan’s syndrome: a drug-induced phenomenon? Oral Surg Oral Med Oral Pathol 70:184–185.[CrossRef][Medline] [Order article via Infotrieve]
• Lamey PJ, McCartan BE, MacDonald DG, MacKie RM (1995). Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:44–49.[Medline] [Order article via Infotrieve]
• Lapostolle F, Borron SW, Bekka R, Baud FJ (1998). Lingual angioedema after perindopril use. Am J Cardiol 81:523.[Medline] [Order article via Infotrieve]
• Laskaris G, Nicolis G (1980). Immunopathology of oral mucosa in bullous pemphigoid. Oral Surg Oral Med Oral Pathol 50:340–345.[Medline] [Order article via Infotrieve]
• Laskaris G, Satriano RA (1993). Drug-induced blistering oral lesions. Clin Dermatol 11:545–550.[Medline] [Order article via Infotrieve]
• Layton D, Pearce GL, Shakir SA (2001). Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Safety 24:703–713.[CrossRef][Medline] [Order article via Infotrieve]
• Lee E, Lee C (1997). Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606–611.[Medline] [Order article via Infotrieve]
• Lind PO, Hurlen B (1988). Desquamative gingivitis responding to treatment with tetracycline: a pilot study. Scand J Dent Res 96:232–234.[Medline] [Order article via Infotrieve]
• Lind PO, Hurlen B, Lyberg T, Aas E (1986). Amalgam-related oral lichenoid reaction. Scand J Dent Res 94:448–451.[Medline] [Order article via Infotrieve]
• Loesche WJ, Bromberg J, Terpenning MS, Bretz WA, Dominguez BL, Grossman NS, et al. (1995). Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J Am Geriatr Soc 43:401–407.[Medline] [Order article via Infotrieve]
• Lombardi ML, De Angelis E, Rossano F, Ruocco V (1993). Imbalance between plasminogen activator and its inhibitors in thiol-induced acantholysis. Dermatology 186:118–122.[Medline] [Order article via Infotrieve]
• Lyell A (1979). Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 100:69–86.[CrossRef][Medline] [Order article via Infotrieve]
• Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K (1999). A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646–651.[CrossRef][Medline] [Order article via Infotrieve]
• Madinier I, Jehl-Pietri C, Monteil RA (1997). [Drug-induced xerostomia]. Ann Med Interne (Paris) 148:398–405.[Medline] [Order article via Infotrieve]
• Mahboob A, Haroon TS (1998). Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 37:833–838.[CrossRef][Medline] [Order article via Infotrieve]
• Maillefert JF, Farge P, Gazet-Maillefert MP, Tavernier C (1997). Mental nerve neuropathy as a result of hepatitis B vaccination. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83:663–664.[Medline] [Order article via Infotrieve]
• Mandel L, Surattanont F, Dourmas M (2001). T-cell lymphoma in the parotid region after cardiac transplant: case report. J Oral Maxillofac Surg 59:673–677.[Medline] [Order article via Infotrieve]
• Mandel SJ, Mandel L (2003). Radioactive iodine and the salivary glands. Thyroid 13:265–271.[CrossRef][Medline] [Order article via Infotrieve]
• Mangrella M, Motola G, Russo F, Mazzeo F, Giassa T, Falcone G, et al. (1998). [Hospital intensive monitoring of adverse reactions of ACE inhibitors]. Minerva Med 89:91–97.[Medline] [Order article via Infotrieve]
• Manor A, Sperling I, Buchner A (1981). Gingival pigmentation associated with antimalarial drugs. Refuat Hapeh Vehashinayim 28(4):13–16.[Medline] [Order article via Infotrieve]
• Markitziu A, Katz J, Pisanty S (1986). Lichenoid lesions of oral mucosa associated with ketoconazole. Mykosen 29:317–322.[Medline] [Order article via Infotrieve]
• Marquart-Elbaz C, Lipsker D, Grosshans E, Cribier B (1999). [Oral ulcers induced by nicorandil: prevalence and clinicopathological aspects]. Ann Dermatol Venereol 126:587–590.[Medline] [Order article via Infotrieve]
• Marshall RI, Bartold PM (1998). Medication induced gingival overgrowth. Oral Dis 4:130–151.[Medline] [Order article via Infotrieve]
• Mascarenhas AK, Allen CM, Loudon J (2001). The association between Viadent use and oral leukoplakia. Epidemiology 12:741–743.[CrossRef][Medline] [Order article via Infotrieve]
• Mascarenhas AK, Allen CM, Moeschberger ML (2002). The association between Viadent use and oral leukoplakia—results of a matched case-control study. J Public Health Dent 62:158–162.[Medline] [Order article via Infotrieve]
• Mattila MJ, Paakkari I (1999). Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 55:85–93.[CrossRef][Medline] [Order article via Infotrieve]
• Mattingly G, Rodu B, Alling R (1993). Quinke’s disease: nonhereditary angioneurotic edema of the uvula. Oral Surg Oral Med Oral Pathol 75:292–295.[Medline] [Order article via Infotrieve]
• Matz H, Bialy-Golan A, Brenner S (1997). Diclofenac: a new trigger of pemphigus vulgaris? Dermatology 195:48–49.[Medline] [Order article via Infotrieve]
• McAllan LH, Adkins KF (1986). Drug-induced palatal pigmentation. Aust Dent J 31:1–4.[Medline] [Order article via Infotrieve]
• McCarron DA (1984). Step-one antihypertensive therapy: a comparison of a centrally acting agent and a diuretic. J Cardiovasc Pharmacol 6(Suppl 5):S853–S858.
• McCartan BE, McCreary CE (1997). Oral lichenoid drug eruptions. Oral Dis 3:58–63.[Medline] [Order article via Infotrieve]
• McCarthy GM, Skillings JR (1991). A prospective cohort study of the orofacial effects of vincristine neurotoxicity. J Oral Pathol Med 20:345–349.[Medline] [Order article via Infotrieve]
• McCarthy GM, Skillings JR (1992). Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer. Oral Surg Oral Med Oral Pathol 74:299–304.[CrossRef][Medline] [Order article via Infotrieve]
• McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998). Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34:484–490.[CrossRef][Medline] [Order article via Infotrieve]
• McQueen A, Behan WM (1982). Immunofluorescence microscopy. The "string of pearls" phenomenon—an immunofluorescent serological finding in patients screened for adverse drug reactions. Am J Dermatopathol 4:155–159.[Medline] [Order article via Infotrieve]
• Meurman JH, Collin HL, Niskanen L, Toyry J, Alakuijala P, Keinanen S, et al. (1998). Saliva in non-insulin-dependent diabetic patients and control subjects: the role of the autonomic nervous system. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86:69–76.[Medline] [Order article via Infotrieve]
• Meyers AD, Barker C, Grossman R, Potsic WP, Jafek BW (1976). Kaposi’s sarcoma of the oropharynx following renal transplantation. Trans Am Acad Ophthalmol Otolaryngol 82:560–562.
• Meyerson MA, Cohen PR, Hymes SR (1995). Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:180–184.[Medline] [Order article via Infotrieve]
• Miller RL, Gould AR, Bernstein ML (1992). Cinnamon-induced stomatitis venenata, clinical and characteristic histopathologic features. Oral Surg Oral Med Oral Pathol 73:708–716.[CrossRef][Medline] [Order article via Infotrieve]
• Milosevic A, Agrawal N, Redfearn P, Mair L (1999). The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). Community Dent Oral Epidemiol 27:283–287.
• Mirbod SM, Ahing SI (2000). Tobacco-associated lesions of the oral cavity: part I. Nonmalignant lesions. J Can Dent Assoc 66:252–256.[Medline] [Order article via Infotrieve]
• Mobacken H, Hersle K, Sloberg K, Thilander H (1984). Oral lichen planus: hypersensitivity to dental restoration material. Contact Dermatitis 10:11–15.[Medline] [Order article via Infotrieve]
• Montoner F, Ortiz M, Capella D, Ruiz J (1990). [Aphthous stomatitis due to captopril]. Aten Primaria 7:79.[Medline] [Order article via Infotrieve]
• Mullen J, Jibson MD, Sweitzer D (2001). A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23:1839–1854.[CrossRef][Medline] [Order article via Infotrieve]
• Murray-Bruce DJ (1966). Salivary gland enlargement and phenylbutazone. Br Med J 5503:1599–1600.
• Nagler RM (1998). Effects of radiotherapy and chemotherapeutic cytokines on a human salivary cell line. Anticancer Res 18(1A):309–314.[Medline] [Order article via Infotrieve]
• Närhi TO, Meurman JH, Ainamo A (1999). Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 15:103–116.[Medline] [Order article via Infotrieve]
• Nederfors T (1996). Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J 116(Suppl):1–70.
• Nicholls MG, Maslowski AH, Ikram H, Espiner EA (1981). Ulceration of the tongue: a complication of captopril therapy. Ann Intern Med 94:659.[Abstract/Free Full Text]
• Noguchi K, Masuda M, Noguchi S, Kubota Y, Hosaka M, Senga Y, et al. (1998). [Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence]. Hinyokika Kiyo 44:687–693.[Medline] [Order article via Infotrieve]
• Ogunwande SA (1989). Halitosis and abuse of antibiotics. Report of a case. Ceylon Med J 34:131–133.[Medline] [Order article via Infotrieve]
• Oikarinen K, Salo T, Kylmaniemi M, Palatsi R, Karhunen T, Oikarinen A (1995). Systemic oral isotretinoin therapy and flow rate, pH, and matrix metalloproteinase-9 activity of stimulated saliva. Acta Odontol Scand 53:369–371.[Medline] [Order article via Infotrieve]
• Ong CS, Cook N, Lee S (2000). Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol 41:242–246.[Medline] [Order article via Infotrieve]
• Ostman PO, Anneroth G, Skoglund A (1994). Oral lichen planus lesions in contact with amalgam fillings: a clinical, histologic, and immunohistochemical study. Scand J Dent Res 102:172–179.[Medline] [Order article via Infotrieve]
• Pajukoski H, Meurman JH, Halonen P, Sulkava R (2001). Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:641–649.[CrossRef][Medline] [Order article via Infotrieve]
• Palmer RA, Ogg G, Allen J, Banerjee A, Ryatt KS, Ratnavel R, et al. (2001). Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285. Br J Dermatol 145:816–820.[CrossRef][Medline] [Order article via Infotrieve]
• Parker M (1975). Persistent parotid pain due to guanacline. Eur J Clin Pharmacol 8:131–134.[Medline] [Order article via Infotrieve]
• Parry J, Porter SL, Scully C, Flint SR, Parry MG (1996). Mucosal lesions due to cocaine use. Br Dent J 180:462–464.[Medline] [Order article via Infotrieve]
• Penneys NS, Ackerman AB, Gottlieb NL (1974). Gold dermatitis. A clinical and histopathological study. Arch Dermatol 109:372–376.[Abstract/Free Full Text]
• Pernu HE, Oikarinen K, Hietanen J, Knuuttila M (1989). Verapamil-induced gingival overgrowth: a clinical, histologic, and biochemic approach. J Oral Pathol Med 18:422–425.[CrossRef][Medline] [Order article via Infotrieve]
• Peroutka SJ, Newman H, Harris H (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277.[Medline] [Order article via Infotrieve]
• Persson RE, Izutsu KT, Truelove EL, Persson R (1991). Differences in salivary flow rates in elderly subjects using xerostomatic medications. Oral Surg Oral Med Oral Pathol 72:42–46.[CrossRef][Medline] [Order article via Infotrieve]
• Pindborg JJ, Reibel J, Roed-Peterson B, Mehta FS (1980). Tobacco-induced changes in oral leukoplakic epithelium. Cancer 45:2330–2336.[Medline] [Order article via Infotrieve]
• Pomara N, Shao B, Choi SJ, Tun H, Suckow RF (2001). Sex-related differences in nortriptyline-induced side-effects among depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 25:1035–1048.[Medline] [Order article via Infotrieve]
• Porter SR, Glover S, Scully C (1990). Oral hyperpigmentation and adrenocortical hypofunction in a patient with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol 70:59–60.[Medline] [Order article via Infotrieve]
• Potgieter GE, Groenewoud G, Jordaan PJ, Hundt HK, Schall R, Kummer M, et al. (2002). Pharmacokinetics of pipamperone from three different tablet formulations. Arzneimittelforschung 52:430–434.[Medline] [Order article via Infotrieve]
• Potts AJ, Hamburger J, Scully C (1987). The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 64:541–543.[CrossRef][Medline] [Order article via Infotrieve]
• Pradalier A, Dry J, Baron JF (1982). [Aphthoid stomatitis induced by labetalol]. Therapie 37:695–697.[Medline] [Order article via Infotrieve]
• Price EJ, Venables PJ (1995). Drug-induced lupus. Drug Safety 12:283–290.[Medline] [Order article via Infotrieve]
• Qunibi WY, Akhtar M, Ginn E, Smith P (1988). Kaposi’s sarcoma in cyclosporine-induced gingival hyperplasia. Am J Kidney Dis 11:349–352.
• Ramadan AE (1969). The association of black hairy tongue with toothpastes containing neomycin. Report of two cases. Egypt Dent J 15:253–256.[Medline] [Order article via Infotrieve]
• Rasmussen HB, Jepsen LV, Brandrup F (1989). Penicillamine-induced bullous pemphigoid with pemphigus-like antibodies. J Cutan Pathol 16:154–157.[CrossRef][Medline] [Order article via Infotrieve]
• Raut A, Huryn J, Pollack A, Zlotolow I (2000). Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:436–441.[Medline] [Order article via Infotrieve]
• Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH (1997). A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 58:112–118.[Medline] [Order article via Infotrieve]
• Read SJ, Crawford DH, Pender MP (1995). Trigeminal sensory neuropathy induced by interferon-alpha therapy. Aust NZ J Med 25:54.[Medline] [Order article via Infotrieve]
• Rees SR, Gibson J (1997). Angioedema and swellings of the orofacial region. Oral Dis 3:39–42.[Medline] [Order article via Infotrieve]
• Reichart PA (1997). Oral ulcerations in HIV infection. Oral Dis 3(Suppl 1):S180–S182.
• Reid JL (2001). Update on rilmenidine: clinical benefits. Am J Hypertens 14:322S–324S.[Medline] [Order article via Infotrieve]
• Rich MW (1996). Drug-induced lupus. The list of culprits grows. Postgrad Med 100:299–308.[Medline] [Order article via Infotrieve]
• Richter WO (1999). [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine]. MMW Fortschr Med 141(49–50):32–36.[Medline] [Order article via Infotrieve]
• Roberts DL, Marks R (1981). Skin reactions to carbamazepine. Arch Dermatol 117:273–275.[Abstract/Free Full Text]
• Robertson WD, Wray D (1992). Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 74:183–185.[Medline] [Order article via Infotrieve]
• Roger M, Gerard D, Leger JM (1998). [Value of tiapride for agitation in the elderly. Review of published studies]. Encephale 24:462–468.[Medline] [Order article via Infotrieve]
• Roujeau JC (1997). Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24:726–729.[Medline] [Order article via Infotrieve]
• Roussel S, Courville P, Peron JM, Delcampe P, Metayer J (1998). [Oral aphthae induced by nicorandil. Anatomopathologic aspects. A propos of a case]. Rev Stomatol Chir Maxillofac 99:207–209.[Medline] [Order article via Infotrieve]
• Ruocco V, Brenner S, Lombardi ML (1996). A case of diet-related pemphigus. Dermatology 192:373–374.[Medline] [Order article via Infotrieve]
• Rushton A (1977). Safety of Hibitane. II. Human experience. J Clin Periodontol 4(5):73–79.[CrossRef][Medline] [Order article via Infotrieve]
• Sabroe RA, Black AK (1997). Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 136:153–158.[CrossRef][Medline] [Order article via Infotrieve]
• Savino LB, Haushalter NM (1992). Lisinopril-induced "scalded mouth syndrome". Ann Pharmacother 26:1381–1382.[Abstract]
• Schachter M (1999). Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens 17(Suppl 3):S37–S39.
• Schatzberg AF (2000). Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61(Suppl 10):31–38.
• Schier JG, Hoffman RS, Nelson LS (2002). Desiccant-induced gastrointestinal burns in a child. Vet Hum Toxicol 44:343–344.[Medline] [Order article via Infotrieve]
• Schubert MM (1991). Oral manifestations of viral infections in immunocompromised patients. Curr Opin Dent 1:384–397.[Medline] [Order article via Infotrieve]
• Schubert MM, Epstein JB, Lloid ME, Cooney E (1993). Oral infections due to cytomegalovirus in immunocompromised patients. J Oral Pathol Med 22:268–273.[CrossRef][Medline] [Order article via Infotrieve]
• Sciubba JJ (1995). Oral leukoplakia. Crit Rev Oral Biol Med 6:147–160.[Abstract/Free Full Text]
• Scott BB (1998). Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 12:277–279.[Medline] [Order article via Infotrieve]
• Scott LJ, Perry CM (2000). Tramadol: a review of its use in perioperative pain. Drugs 60:139–176.[CrossRef][Medline] [Order article via Infotrieve]
• Scully C (1992). Oral infections in the immunocompromised patient. Br Dent J 172(11):401–407.[CrossRef][Medline] [Order article via Infotrieve]
• Scully C (2003). Drug effects on salivary glands; dry mouth. Oral Dis 9:165–176.[CrossRef][Medline] [Order article via Infotrieve]
• Scully C, Challacombe SJ (2002). Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 13:397–408.[Abstract/Free Full Text]
• Scully C, Diz DP (2001). Orofacial effects of antiretroviral therapies. Oral Dis 7:205–210.[Medline] [Order article via Infotrieve]
• Scully C, Porter SR (1997). The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg 16:308–313.[Medline] [Order article via Infotrieve]
• Scully C, El Kabir M, Samaranayake LP (1994). Candida and oral candidosis: a review. Crit Rev Oral Biol Med 5:125–157.[Abstract/Free Full Text]
• Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, et al. (1998). Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 9:86–122.[Abstract/Free Full Text]
• Scully C, El Kabir M, Greenman J, Porter SR, Mutlu S, Barton I, et al. (1999). The effects of mouth rinses and dentifrice-containing magnesium monoperoxyphthalate (mmpp) on oral microflora, plaque reduction, and mucosa. J Clin Periodontol 26:234–238.[Medline] [Order article via Infotrieve]
• Scully C, Bagan J, Eisen D, Porter S, Rogers R (2000). Dermatology of the lips. Oxford: Isis Medical Media.
• Seedat YK (1979). Aphthous ulcers of mouth from captopril. Lancet 2:1297–1298.[Medline] [Order article via Infotrieve]
• Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y (1999). Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 55:583–587.[CrossRef][Medline] [Order article via Infotrieve]
• Seymour RA, Jacobs DJ (1992). Cyclosporin and the gingival tissues. J Clin Periodontol 19:1–11.[CrossRef][Medline] [Order article via Infotrieve]
• Seymour RA, Thomason JM, Nolan A (1997). Oral lesions in organ transplant patients. J Oral Pathol Med 26(7):297–304.[Medline] [Order article via Infotrieve]
• Shapiro M, Jimenez S, Werth VP (2000). Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 42:297–299.[Medline] [Order article via Infotrieve]
• Shotts RH, Scully C, Avery CM, Porter SR (1999). Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87:706–707.[CrossRef][Medline] [Order article via Infotrieve]
• Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, et al. (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14:322–329.[Medline] [Order article via Infotrieve]
• Shuttleworth D, Graham-Brown RA, Hutchinson PE, Jolliffe DS (1985). Cicatricial pemphigoid in D-penicillamine treated patients with rheumatoid arthritis—a report of three cases. Clin Exp Dermatol 10:392–397.[CrossRef][Medline] [Order article via Infotrieve]
• Siegel MA, Balciunas BA (1991). Medication can induce severe ulcerations. J Am Dent Assoc 122:75–77.[Abstract]
• Skoglund A, Egelrud T (1991). Hypersensitivity reactions to dental materials in patients with lichenoid oral mucosal lesions and in patients with burning mouth syndrome. Scand J Dent Res 99:320–328.[Medline] [Order article via Infotrieve]
• Smart ER, Macleod RI, Lawrence CM (1995). Resolution of lichen planus following removal of amalgam restorations in patients with proven allergy to mercury salts: a pilot study. Br Dent J 178:108–112.[CrossRef][Medline] [Order article via Infotrieve]
• Smith RG, Burtner AP (1994). Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist 14:96–102.[Medline] [Order article via Infotrieve]
• Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S (1999). The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 14:851–857.[CrossRef][Medline] [Order article via Infotrieve]
• Sreebny LM, Schwartz SS (1997). A reference guide to drugs and dry mouth. 2nd ed. Gerodontology 14:33–47.[CrossRef][Medline] [Order article via Infotrieve]
• Srisurapanont M, Disayavanish C, Taimkaew K (2000). Quetiapine for schizophrenia. Cochrane Database Syst Rev (2):CD000967.
• Streckfus CF (1995). Salivary function and hypertension: a review of the literature and a case report. J Am Dent Assoc 126:1012–1017.[Abstract/Free Full Text]
• Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP (1996). Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol 42:313–318.[Medline] [Order article via Infotrieve]
• Suzuki N, Saito K, Shiota T, Akizuki H, Michiwaki Y, Ohno K, et al. (1983). [Fundamental and clinical studies of long acting amoxicillin granules in oral and maxillofacial surgery infections]. Jpn J Antibiot 36:452–463.[Medline] [Order article via Infotrieve]
• Syrjanen SM, Syrjanen KJ (1979). Hyperplastic gingivitis in a child receiving sodium valproate treatment. Proc Finn Dent Soc 75:95–98.[Medline] [Order article via Infotrieve]
• Taricco M, Adone R, Pagliacci C, Telaro E (2000). Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev (2):CD001131.
• Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP (1995). Omeprazole and dry mouth. Scand J Gastroenterol 30:216–218.[Medline] [Order article via Infotrieve]
• Thomason JM, Kelly PJ, Seymour RA (1996). The distribution of gingival overgrowth in organ transplant patients. J Clin Periodontol 23:367–371.[Medline] [Order article via Infotrieve]
• Thomson WM, Chalmers JM, Spencer AJ, Slade GD (2000). Medication and dry mouth: findings from a cohort study of older people. J Public Health Dent 60:12–20.[Medline] [Order article via Infotrieve]
• Thomson WM, Spencer AJ, Slade GD, Chalmers JM (2002). Is medication a risk factor for dental caries among older people? Community Dent Oral Epidemiol 30:224–232.[Medline] [Order article via Infotrieve]
• Timms MS, Sloan P, Balzan AP (1988). Idiopathic plasmacytosis of the oral and supraglottic mucosa. J Laryngol Otol 102:646–648.[Medline] [Order article via Infotrieve]
• Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, et al. (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59:62–69.[Abstract/Free Full Text]
• Toren A, Ackerstein A, Gazit D, Or R, Raveh D, Kupolovicz U, et al. (1996). Oral tuberculosis following autologous bone marrow transplantation for Hodgkin’s disease with interleukin-2 and alpha-interferon immunotherapy. Bone Marrow Transplant 18:209–210.[Medline] [Order article via Infotrieve]
• Torrelo A, Soria C, Rocamora A, Moreno R, Ledo A (1990). Lichen planus-like eruption with esophageal involvement as a result of cyanamide. J Am Acad Dermatol 23:1168–1169.[Medline] [Order article via Infotrieve]
• Torresani C, Nannini R, Bondi A, Guadagni M, Manara GC (1994). Erosive oral lichen planus due to sensitization to cobalt chloride. Clin Exp Dermatol 19:535–536.[Medline] [Order article via Infotrieve]
• Triantos D, Porter SR, Scully C, Teo CG (1997). Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 25:1392–1396.[Medline] [Order article via Infotrieve]
• Trindade E, Menon D, Topfer LA, Coloma C (1998). Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159:1245–1252.[Abstract]
• Troy JL, Silvers DN, Grossman ME, Jaffe IA (1981). Penicillamine-associated pemphigus: is it really pemphigus? J Am Acad Dermatol 4:547–555.[CrossRef][Medline] [Order article via Infotrieve]
• Tur E, Brenner S (1998). Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol 134:1406–1410.[Abstract/Free Full Text]
• Ulmer JL, Garvey MJ (1992). Fatal angioedema associated with lisinopril. Ann Pharmacother 26:1245–1246.[Abstract]
• Valentine C, Deenmamode J, Sherwood R (1992). Xerostomia associated with didanosine. Lancet 340:1542–1543.[Medline] [Order article via Infotrieve]
• Valsecchi R, Cainelli T (1992). Gingival hyperplasia induced by erythromycin. Acta Derm Venereol 72:157.[Medline] [Order article via Infotrieve]
• Van den Haute V, Antoine JL, Lachapelle JM (1989). Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 179:10–13.[Medline] [Order article via Infotrieve]
• Van Dis ML, Parks ET (1995). Prevalence of oral lichen planus in patients with diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:696–700.[Medline] [Order article via Infotrieve]
• van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A (2003). Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 75:788–791.[CrossRef][Medline] [Order article via Infotrieve]
• van Joost T (1974). Incidence of circulating antibodies reactive with basal cells of skin in drug reactions. Acta Derm Venereol 54:183–187.[Medline] [Order article via Infotrieve]
• Varga E, Tyldesley WR (1991). Carcinoma arising in cyclosporin-induced gingival hyperplasia. Br Dent J 171:26–27.[Medline] [Order article via Infotrieve]
• Vasile JS, Steingard S (1995). Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 56:511–513.[Medline] [Order article via Infotrieve]
• Vassileva S (1998). Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 16:379–387.[CrossRef][Medline] [Order article via Infotrieve]
• Velthuis PJ, Hendrikse JC, Nefkens JJ (1985). Combined features of pemphigus and pemphigoid induced by penicillamine. Br J Dermatol 112:615–619.[Medline] [Order article via Infotrieve]
• Versi E, Appell R, Mobley D, Patton W, Saltzstein D (2000). Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95:718–721.[Medline] [Order article via Infotrieve]
• Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, et al. (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31–37.[Medline] [Order article via Infotrieve]
• Vissink A, van Nieuw Amerongen A, Wesseling H, and ’s-Gravenmade EJ (1992). [Dry mouth; possible cause—pharmaceuticals]. Ned Tijdschr Tandheelkd 99(3):103–112.[Medline] [Order article via Infotrieve]
• Vlasses PH, Rotmensch HH, Ferguson RK, Sheaffer SL (1982). "Scalded mouth" caused by angiotensin-converting-enzyme inhibitors. Br Med J (Clin Res Ed) 284:1672–1673.
• Vleeming W, van Amsterdam JG, Stricker BH, De Wildt DJ (1998). ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Safety 18:171–188.[CrossRef][Medline] [Order article via Infotrieve]
• Wadworth AN, McTavish D (1993). Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 3:441–459.[Medline] [Order article via Infotrieve]
• Wahlbeck K, Cheine M, Essali MA (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (2):CD000059.
• Watson IB, MacDonald DG (1974). Amodioquine induced oral pigmentation—a light and electron microscopic study. J Oral Pathol 3:16–21.[Medline] [Order article via Infotrieve]
• Watt-Smith S, Mehta K, Scully C (2001). Mefloquine-induced trigeminal sensory neuropathy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:163–165.[Medline] [Order article via Infotrieve]
• Weintraub M, Sundaresan PR, Schuster B, Ginsberg G, Madan M, Balder A, et al. (1992). Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 51:595–601.[Medline] [Order article via Infotrieve]
• Wellington K, Jarvis B (2001). Cetirizine/pseudoephedrine. Drugs 61:2231–2240.[Medline] [Order article via Infotrieve]
• Wellington K, Perry CM (2001). Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 15:643–669.[CrossRef][Medline] [Order article via Infotrieve]
• Westbury LW, Najera A (1997). Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. J Periodontol 68:84–91.[Medline] [Order article via Infotrieve]
• White JW Jr, Olsen KD, Banks PM (1986). Plasma cell orificial mucositis. Report of a case and review of the literature. Arch Dermatol 122:1321–1324.[Abstract/Free Full Text]
• Wiesenfeld D, Martin A, Scully C, Thomson J (1982). Oral manifestations in linear IgA disease. Br Dent J 153:398–399.[Medline] [Order article via Infotrieve]
• Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK (2002). Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 42:49–55.[CrossRef][Medline] [Order article via Infotrieve]
• Wishart JM, Hodge JL, Greig DE (1981). Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro-10-9359) Tigason. NZ Med J 94:307–308.[Medline] [Order article via Infotrieve]
• Wolf R, Brenner S (1994). An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology 189:1–4.[Medline] [Order article via Infotrieve]
• Wolf R, Ruocco V (1997). Gaining more insight into the pathomechanisms of thiol-induced acantholysis. Med Hypotheses 48:107–110.[CrossRef][Medline] [Order article via Infotrieve]
• Wolf R, Tamir A, Brenner S (1991). Drug-induced versus drug-triggered pemphigus. Dermatologica 182(4):207–210.[Medline] [Order article via Infotrieve]
• Wynn RL, Meiller TF (2001). Drugs and dry mouth. Gen Dent 49:10–12, 14.[Medline] [Order article via Infotrieve]
• Zacny JP (2001). Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend 63:23–28.[CrossRef][Medline] [Order article via Infotrieve]
• Zinner NR, Mattiasson A, Stanton SL (2002). Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 50:799–807.[CrossRef][Medline] [Order article via Infotrieve]
• Zwar N, Richmond R (2002). Bupropion sustained release. A therapeutic review of Zyban. Aust Fam Physician 31:443–447.[Medline] [Order article via Infotrieve]

Critical Reviews in Oral Biology & Medicine, Vol. 15, No. 4, 221-239 (2004)
DOI: 10.1177/154411130401500405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. I. Fortoul, M. Velez-Cruz, S. Antuna-Bizarro, L. F. Montano, V. Rodriguez-Lara, and L. Saldivar-Osorio Morphological changes in the tongue as a consequence of manganese inhalation in a murine experimental model: Light and scanning electron microscopic analysis J. Electron Microsc. (Tokyo), August 27, 2009; (2009) dfp041v1. [Abstract] [Full Text] [PDF]

				C.J. Tredwin, C. Scully, and J.-V. Bagan-Sebastian Drug-induced Disorders of Teeth Journal of Dental Research, July 1, 2005; 84(7): 596 - 602. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Scully, C. Articles by Bagan, J.-V. Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?